Aging
Navigate
Submit an Article
Research Paper|Volume 13, Issue 1|pp. 450–459
Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis
Back to articleFigure 1(1 of 8)
100%
Figure 1
Figure 1.The PRISMA flow chart summarizing the identification process of eligible studies. WHO ICTRP, World Health Organization International Clinical Trials Registry Platform; PARPi, PARP inhibitor; RCT, randomized controlled trial.